ロード中...
Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure
In order to limit 5-fluorouracil (5-FU) toxicity, some health agencies recommend evaluating dihydropyrimidine dehydrogenase (DPD) deficiency before any 5-FU treatment introduction. In our study, we investigated relationships between 5-FU clearance and markers of DPD activity such as uracilemia (U),...
保存先:
| 出版年: | Pharmaceuticals (Basel) |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7700344/ https://ncbi.nlm.nih.gov/pubmed/33238487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13110416 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|